Brief: Biohaven Presents Oncology Program Updates And Preliminary Clinical Data
28/05/2025 12:39
May 28 (Reuters) - Biohaven Ltd BHVN.N: BIOHAVEN PRESENTS ONCOLOGY PROGRAM UPDATES AND PRELIMINARY CLINICAL DATA SHOWCASING INNOVATIVE TROP2 AND FGFR3 ANTIBODY DRUG CONJUGATES (ADCS) INCORPORATING NOVEL TOPOIX PAYLOAD WITH POTENTIAL TO TREAT A WIDE VARIETY OF TUMORS Source text: ID:nPn2wsJXHa Further company coverage: BHVN.N ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Biohaven
See all newsActing US FDA chief meets with rare disease groups to mend fences (updated)
Acting US FDA chief meets with rare disease groups to mend fences
Brief: Biohaven Reports New Clinical Data In Epilepsy With Opakalim, A Selective Kv7.2/7.3 Activator, Highlighting Seizure Control And Markedly Differentiated Tolerability Profile
Brief: Biohaven Files For Offering Of Up To $350 Million Common Shares - SEC Filing
Brief: Biohaven Ltd Files For Mixed Shelf Offering Size Not Disclosed - SEC Filing